138 related articles for article (PubMed ID: 10631454)
1. Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA.
Sausville EA; Feigal E
Ann Oncol; 1999 Nov; 10(11):1287-91. PubMed ID: 10631454
[No Abstract] [Full Text] [Related]
2. How does a drug get to phase III trials?
Reynolds T
J Natl Cancer Inst; 2000 Oct; 92(19):1555. PubMed ID: 11018084
[No Abstract] [Full Text] [Related]
3. Oncology's first Phase 0 trial.
Rowan K
J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
[No Abstract] [Full Text] [Related]
4. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
5. Japan works to shorten "drug lag," boost trials of new drugs.
Sinha G
J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
[No Abstract] [Full Text] [Related]
6. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
7. NCI, FDA to collaborate on speeding up drug discovery.
Arnold K
J Natl Cancer Inst; 2003 Aug; 95(16):1192. PubMed ID: 12928341
[No Abstract] [Full Text] [Related]
8. From serendipity to design: the evolution of drug development in oncology.
Markman M; Peereboom DM
Cleve Clin J Med; 1997 Mar; 64(3):155-63. PubMed ID: 9068226
[TBL] [Abstract][Full Text] [Related]
9. Slow start to phase 0 as researchers debate value.
Twombly R
J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
[No Abstract] [Full Text] [Related]
10. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
11. Approaches to the development and marketing approval of drugs that prevent cancer.
Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
[TBL] [Abstract][Full Text] [Related]
12. Rapid reporting and review of an increased incidence of a known adverse event.
Sargent DJ; Goldberg RM; Mahoney MR; Hillman DW; McKeough T; Hamilton SF; Darcy JM; Anderson VL; Krook JE; O'Connell MJ
J Natl Cancer Inst; 2000 Jun; 92(12):1011-3. PubMed ID: 10861314
[No Abstract] [Full Text] [Related]
13. Accelerated approval seen as triumph and roadblock for cancer drugs.
Susman E
J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
[No Abstract] [Full Text] [Related]
14. Pediatric drug research--the road less traveled.
Holdsworth MT
Ann Pharmacother; 2003 Apr; 37(4):586-91. PubMed ID: 12659620
[No Abstract] [Full Text] [Related]
15. Development of investigational radiation modifiers.
Colevas AD; Brown JM; Hahn S; Mitchell J; Camphausen K; Coleman CN;
J Natl Cancer Inst; 2003 May; 95(9):646-51. PubMed ID: 12734315
[No Abstract] [Full Text] [Related]
16. Multidrug resistance: can new drugs help chemotherapy score against cancer?
Goldman B
J Natl Cancer Inst; 2003 Feb; 95(4):255-7. PubMed ID: 12591977
[No Abstract] [Full Text] [Related]
17. HIV vector challenges gene therapy oversight.
Fox JL
Nat Biotechnol; 1997 Sep; 15(9):832. PubMed ID: 9306390
[No Abstract] [Full Text] [Related]
18. Translational medicine and the National Institutes of Health road map: steep grades and tortuous curves.
Humes HD
J Lab Clin Med; 2005 Aug; 146(2):51-4. PubMed ID: 16099234
[No Abstract] [Full Text] [Related]
19. Balancing safety, effectiveness, and public desire: the FDA and cancer.
Conti R
Issue Brief (Commonw Fund); 2003 Apr; (615):1-6. PubMed ID: 12693391
[No Abstract] [Full Text] [Related]
20. Competitors try collaboration to speed drug development.
Patlak M
J Natl Cancer Inst; 2010 Jun; 102(12):841-3. PubMed ID: 20530762
[No Abstract] [Full Text] [Related]
[Next] [New Search]
